This activity will provide learners with the latest developments in translational medicine for leukemia, lymphoma, and myeloma and how these developments can be incorporated into regimens to improve the outcome of patients with these diseases.
Upon completion of this activity, participants should be better able to:
The Maurice & Marguerite Liberman Distinguished Endowed Chair, Cancer Research
UNM Distinguished Professor, Pathology
UNM School of Medicine
Director & CEO
University of New Mexico Comprehensive Cancer Center
Albuquerque, NM
Harold and Virginia Lash/David Lash Chair, Lymphoma Research
Chief, Lymphoma Division
Dana-Farber Cancer Institute
Boston, MA
Bosworth Chair, Cancer Biology
Professor of Pediatrics and Microbiology, Immunology and Tropical Medicine
Director, Center for Cancer and Immunology Research
Director, Program for Cell Enhancement and Technologies for Immunotherapy
Children’s National Health System
The George Washington University School of Medicine and Health Sciences
Washington, DC
George P. Canellos, MD and Jean S. Canellos Professor, Medicine
Harvard Medical School
Chair, Department of Medical Oncology
Dana-Farber Cancer Institute,
Boston, MA
Investigator, Howard Hughes Medical Institute
Chief, Division of Oncology
Director, Center for Childhood Cancer Research
Jeffrey E. Perelman Distinguished Chair, Department of Pediatrics
Children’s Hospital of Philadelphia
Professor, Department of Pediatrics
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, PA
Featured RMEI CE Activities
Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources
